Last reviewed · How we verify

NCT05505786

The Effects of Increased vs. Traditional Squat Stance Width on Performance Indices in Elite Rugby League Players

Completed NA Last updated 6 September 2022
What this trial tests

NA trial testing Normal stance width in Sports Performance in 26 participants. Completed in 1 April 2022.

Timeline
1 October 2021
Primary endpoint
1 December 2021
1 April 2022

Quick facts

Lead sponsorUniversity of Central Lancashire
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposebasic science
Enrollment26
Start date1 October 2021
Primary completion1 December 2021
Estimated completion1 April 2022
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Central Lancashire

Who can join

Adults 18 to 35, male only, with Sports Performance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The back squat is a commonly utilized resistance training exercise for the promotion of both performance and musculoskeletal health. There are a range of manipulations that can be made to the setup of this resistance exercise, with once such adaptation being the stance width when performing the exercise. This intervention aims to explore the effects of increasing the stance with on performance indices in elite rugby league players.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sports Performance

Currently open trials in the same condition.

Other University of Central Lancashire trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05505786.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing